At CCHMC, our Comprehensive Neuromuscular Center provides expert, comprehensive, and compassionate care for infants, children, teenagers, and young adults with neuromuscular conditions. As one of the largest referral centers for pediatric neuromuscular care in the Midwest, we bring together a highly experienced multidisciplinary team—including specialists in neurology, orthopedic surgery, physiatry, pulmonology, genetics, psychology, nutrition and physical therapy—to deliver the highest level of diagnostic and treatment services. A unique feature of our program is our coordinated clinic model, allowing patients to see multiple specialists in one place and at the same time, ensuring seamless, personalized care designed to maximize each patient’s health and quality of life. Our center is engaged in advancing care for Charcot–Marie–Tooth (CMT) disease through collaboration with the CMT community and the CMTA network, expanding access to specialized expertise, clinical research, and emerging therapies while fostering partnerships that continually advance neuromuscular care, research, and education.
Meghan McAnally, MD, MPH
Cincinnati Children’s Hospital Medical Center
Dr. McAnally is a pediatric neurologist with subspecialty training in adult and pediatric neuromuscular medicine and additional clinical and translational research training in genetic neuromuscular disorders of childhood at the National Institutes of Health. She specializes in the diagnosis and management of rare and ultra-rare genetic neuromuscular disorders, including Charcot–Marie–Tooth (CMT) disease.
Her research focuses on developing clinical outcome measures and identifying biomarkers to track disease progression and therapeutic response. She has a particular interest in the use of muscle ultrasound to characterize imaging features of genetic neuromuscular disorders as both a diagnostic tool and a biomarker to support therapeutic development. Together with the multidisciplinary team at Cincinnati Children’s, Dr. McAnally is committed to delivering the highest quality evidence-based care while expanding access to emerging therapies for patients with rare neuromuscular diseases.
